DN022150 Trial Initiated for Advanced Pancreatic Cancer with KRAS G12D Mutation
A trial has been initiated to evaluate DN022150 against standard chemotherapy in patients with advanced pancreatic cancer and KRAS G12D mutation.
Asset / Drug
Drug and asset intelligence for DN022150 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.